Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Revolution Medicines (RVMD) EBIT (2019 - 2025)

Revolution Medicines has reported EBIT over the past 7 years, most recently at $583.2 million for Q4 2025.

  • Quarterly results put EBIT at $583.2 million for Q4 2025, up 369.6% from a year ago — trailing twelve months through Dec 2025 was -$237.6 million (up 65.55% YoY), and the annual figure for FY2025 was -$237.6 million, up 65.55%.
  • EBIT for Q4 2025 was $583.2 million at Revolution Medicines, up from -$315.3 million in the prior quarter.
  • Over the last five years, EBIT for RVMD hit a ceiling of $583.2 million in Q4 2025 and a floor of -$315.3 million in Q3 2025.
  • Median EBIT over the past 5 years was -$92.7 million (2022), compared with a mean of -$93.0 million.
  • Biggest five-year swings in EBIT: tumbled 191.67% in 2023 and later surged 369.6% in 2025.
  • Revolution Medicines' EBIT stood at -$52.9 million in 2021, then decreased by 16.62% to -$61.7 million in 2022, then tumbled by 191.67% to -$180.0 million in 2023, then decreased by 20.18% to -$216.3 million in 2024, then surged by 369.6% to $583.2 million in 2025.
  • The last three reported values for EBIT were $583.2 million (Q4 2025), -$315.3 million (Q3 2025), and -$264.7 million (Q2 2025) per Business Quant data.